protein

Recombinant Human Small Ubiquitin-Related Modifier 1

MBS142881

0.01 mg

140 USD

Recombinant Protein

Recombinant Human Small Ubiquitin-Related Modifier 1

Small Ubiquitin-Related Modifier 1

SUMO1 Human; SUMO1 Human Recombinant; Small ubiquitin-related modifier 1; SUMO-1; Sentrin; Ubiquitin-like protein SMT3C; SMT3 homolog 3; Ubiquitin-homology domain protein PIC1; Ubiquitin-like protein UBL1; GAP-modifying protein 1; GMP1; SUMO1; SMT3C; SMT3H3; UBL1; PIC1; SMT3; DAP-1; OFC10; SENP2

small ubiquitin-related modifier 1 isoform a; Small ubiquitin-related modifier 1; small ubiquitin-related modifier 1; GAP modifying protein 1; SMT3 homolog 3; SMT3 suppressor of mif two 3 homolog 1; sentrin; ubiquitin-homology domain protein PIC1; ubiquitin-like protein SMT3C; ubiquitin-like protein UBL1; small ubiquitin-like modifier 1; GAP-modifying protein 1; GMP1; SMT3 homolog 3; Sentrin; Ubiquitin-homology domain protein PIC1; Ubiquitin-like protein SMT3C; Smt3C; Ubiquitin-like protein UBL1

SUMO1

SUMO1; SUMO1; DAP1; GMP1; PIC1; SMT3; UBL1; OFC10; SENP2; SMT3C; SMT3H3; SMT3C; SMT3H3; UBL1; SUMO-1; GMP1; Smt3C

SUMO1_HUMAN

E Coli

101

Greater than 98.0% as determined by (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.

10mM sodium chloride, 100mM imidazole, 0.5mM PMSF, 1mM DTT and 10% glycerol. Sterile Filtered clear solution.

SUMO1 although stable at 4 degree C for 1 week, should be stored desiccated below -18 degree C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please prevent freeze-thaw cycles.

RECOMBINANT & NATURAL PROTEINS; Recombinant Proteins; Ubiquitin

Description: The active human SUMO-I (the 1-97 animo acid region of the Ubiquitin-like protein SMT3C precursor). The enzyme contains a single polypeptide band of 11 kDa. The predicted molecular weight of hSOMO I is 11 kDa. The The final fraction of enzyme contains single polypeptide band of approximately 20 kDa on SDS PAGE. Introduction: SUMO1 is a protein that belongs to the SUMO (small ubiquitin-like modifier) protein family. SUMO1 functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. Still, unlike ubiquitin which targets proteins for degradation, SUMO1 is involved in a variety of cellular processes, for example nuclear transport, transcriptional regulation, apoptosis, and protein stability. SUMO1 is not active until the last four amino acids of the carboxy-terminus are cleaved off.

54792065

NP_001005781.1

NM_001005781.1

P63165

8,799 Da

Androgen Receptor Signaling Pathway (198806); Cytokine Signaling In Immune System Pathway (366171); Diurnally Regulated Genes With Circadian Orthologs Pathway (198813); Immune System Pathway (106386); Interferon Signaling Pathway (187103); Interferon Gamma Signaling Pathway (187106); Metabolism Of Proteins Pathway (106230); Nuclear Pore Complex Pathway (470351); Nuclear Pore Complex Pathway (890636); Post-translational Protein Modification Pathway (161012)

This gene encodes a protein that is a member of the SUMO (small ubiquitin-like modifier) protein family. It functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. It is not active until the last four amino acids of the carboxy-terminus have been cleaved off. Several pseudogenes have been reported for this gene. Alternate transcriptional splice variants encoding different isoforms have been characterized. [provided by RefSeq, Jul 2008]

SUMO1: Ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Involved for instance in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. May also regulate a network of genes involved in palate development. Interacts with SAE2, UBE2I, RANBP2, PIAS1 and PIAS2. Interacts with PARK2. Covalently attached to a number of proteins such as IKFZ1, PML, RANGAP1, HIPK2, SP100, p53, p73-alpha, MDM2, JUN, DNMT3B and TDG. Also interacts with HIF1A, HIPK2, HIPK3, CHD3, EXOSC9, RAD51 and RAD52. Interacts with USP25 (via ts SIM domain); the interaction weakly sumoylates USP25. Belongs to the ubiquitin family. SUMO subfamily. Protein type: Nuclear receptor co-regulator; Ubiquitin-like modifier. Chromosomal Location of Human Ortholog: 2q33. Cellular Component: nucleoplasm; PML body; nuclear membrane; cytoplasm; dendrite; nucleolus; fibrillar center; nuclear speck; synapse; nuclear pore; nucleus. Molecular Function: protein binding; ubiquitin protein ligase binding; SUMO ligase activity; transcription factor binding. Biological Process: positive regulation of protein complex assembly; cellular protein metabolic process; regulation of protein localization; protein sumoylation; negative regulation of transcription factor activity; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; cytokine and chemokine mediated signaling pathway; PML body organization and biogenesis; palate development; post-translational protein modification; negative regulation of transcription, DNA-dependent; DNA repair; negative regulation of DNA binding. Disease: Orofacial Cleft 10

0.01 mg

140 USD

0.05 mg

205

1 mg

1375